Compare Organon & Co. Common Stock (OGN) vs Zscaler Inc (ZS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs Zscaler Inc — how do they compare? Organon & Co. Common Stock trades at $13.58 (market cap $3.62B), while Zscaler Inc trades at $218.14 (market cap $36.81B). The key difference: Zscaler Inc is far larger — about 10.2× Organon & Co. Common Stock's market cap, and Organon & Co. Common Stock pays a 0.58% dividend while Zscaler Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and Zscaler Inc for 41 Days on average.
| OGN | ZS | |
|---|---|---|
Market Cap | $3.62B | $36.81B |
Volume | 2,892,999 | 2,661,492 |
Sector | Health | Technology |
52-Week High | $13.81 | $336.27 |
52-Week Low | $5.70 | $118.05 |
Typical Hold Time | 0 Days | 41 Days |
Enterprise Value | $11.04B | $35.20B |
Dividend Yield | 0.58% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Zscaler (ZS) trades at $220.79, down 2.21% on the day, amid mixed signals. The stock shows strong technical momentum with bullish moving averages, but RSI suggests potential overbought conditions. Fundamentally, revenue growth is robust, rising from $1.1B in 2022 to $2.67B in 2025, though the company remains unprofitable with a net income margin of -1.88%. Recent news includes executive changes and an upcoming Investor Day on October 6, 2026.
The outlook is cautiously optimistic. Analyst consensus is strongly bullish with a $222.83 price target, but risks include persistent losses, competitive pressures, and insider selling. Upside hinges on AI-driven bookings growth and execution stability post-CRO transition. Investors should weigh high valuation multiples against the company's growth trajectory and market position in cybersecurity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About Zscaler Inc
Zscaler is a security-as-a-service firm that offers its customers cloud-delivered solutions for protecting user devices and data. The firm leverages its position in 150 colocation data centers to deliver traditionally appliance-based security functionality, such as firewalls and sandboxes, as a completely cloud-native platform. The firm focuses on large enterprise customers and offers two primary product suites: Zscaler Internet Access, which securely connects users to externally managed application and websites (such as Salesforce and Google), and Zscaler Private Access, which securely connects users to internally managed applications. Both product suites encompass a broad gamut of capabilities situated across the traditional security stack.
Read more on ZS →
